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Cardiovascular disease is the leading cause of death in the United States 
accounting for approximately 1 in every 3 deaths. Many efforts have been made to reduce 
the mortality rate after a MI by analyzing and possibly manipulating the immune system 
response following an MI.  Immediately after an MI has occurred, pro-inflammatory 
macrophages (M1) are recruited at the affected site. M1 are responsible for clearing dead 
cells and debris. Following the M1 response, wound healing (M2) macrophages, 
responsible for angiogenesis and cell regeneration, are recruited at the site.  Although the 
M1 subset is required for proper wound healing, prolonged activation of this macrophage 
subset attributes to cell fibrosis and tissue scaring. This study initially aims in modulation 
of macrophages to a M2 phenotype utilizing IL-4 after an MI occurs. The secondary aim 
is delivery of IL-4 to the heart site utilizing a PEG-MAL hydrogel. This study could 
prove that delivery of IL-4 to the heart could suppress inflammatory signals after an MI 
and lead to a healing response. In vitro studies in RAW and bone marrow macrophages 
indicated IL-4 leads to an increase in the MRC1 and Arginase 1, M2 markers, and 
macrophages stimulated with lipopolysaccharide (LPS) and interferon gamma increased 
M1 markers nitrite and tumor necrosis factor alpha. The addition of both M1 and M2 
stimuli simultaneously increased Arginase 1 and nitrite production significantly. The IL-4 
treated media from the In vitro macrophages increased cardiac progenitor cell migration 
by 70% relative to the control. This shows that IL-4 differentiated macrophages can 
communicate with other cells crucial to healing. Knowledge of the effects of IL-4 after a 







 Cardiovascular disease is the leading cause of death in the United States 
accounting for approximately 1 in every 3 deaths.  Approximately 83.6 million American 
adults have one or more types of cardiovascular disease in which 7.6 million people are 
subject to myocardial infarction (MI), which is the most common cause of heart failure.[1] 
An MI is caused by a blockage in the coronary artery that delivers blood to the left 
ventricle. [1] After a MI occurs, there is a substantial loss of cardiomyocytes. In most 
cases, a non-contractile scar formation in the myocardium occurs and leads to impaired 
ventricular function. A key factor in this processes is the inflammatory response to the 
injury.[2] Most of the efforts to repair the heart after a MI have focused on stem cell, gene 
or growth factor delivery to the injured heart, but yet to be clinically successful.[3] 
However, Macrophages, central to this inflammatory process have been largely 
overlooked as therapeutic targets.  Recent studies have shown that immediately after an 
MI has occurred, pro-inflammatory macrophages (M1) are recruited at the affected site. 
M1 macrophages are responsible for clearing dead cells and debris. Following the M1 
response, anti-inflammatory (M2) macrophages, responsible for wound healing and tissue 
repair, are recruited at the site. [4]  The pro-inflammatory immune response lasts around 
four days, the shift towards the anti-inflammatory immune response takes place between 
day 4 and 7. [4]Although the M1 subset is required initially, prolonged activation of this 
macrophage subset attributes to adverse cardiac remodeling characterized by fibrosis and 
non-contractile scar tissue formation. [5,6] Therefore, optimal healing response after MI 
requires a balancing act of the biphasic macrophage response. Activation of M2 
macrophages earlier during the course of inflammation following MI via external 
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intervention could trigger repair mechanisms and release of complementary factors that 
can bias cardiac cell towards a regenerative outcome. Thus, modulating the immune 
response could hold tremendous potential as a therapeutic strategy for chronic MI. This 
research aims to modulate the cardiac macrophage phenotype in the heart by delivering 
the M2-polarizing cytokine IL-4 using a hydrogel delivery system in a rat model of 
experimental MI. This treatment is expected to favorably shift the macrophage subsets in 
the infarcted heart from pro-inflammatory to a reparative phenotype and create a pro-
regenerative environment to better heal the heart. 
  
Macrophage Activation 
 The M1 and M2 phenotypic characterizations are actually extremes of a spectrum 
of phenotypes that vary in functionality: host defense, wound healing, and immune 
regulation.[7] In vitro the stimuli for macrophage activation it is well characterized. M1 
activation is induced by lipopolysaccharide (LPS) and Th1-related cytokines, such as 
interferon gamma (IFNy), where as M2 activation is induced by glucocorticoids or Th2-
related cytokines.[8] The M2 subset is further divided into M2a, M2b, and M2c. M2a, 
characterized by the wound-healing phenotype, is activated by interleukin 4 (IL-4) and 
interleukin 13. M2b and M2c are characterized with a regulatory phenotype. M2b 
activation is achieved through immune complex with toll-like receptor ligand and M2c 
activation is induced by IL-10.[7,8] Although In vitro macrophage activation is well 
characterized, it is unable to mimic the complex environment observed in In vivo 
activation.  When macrophages are polarized to M1 or M2 (M2a) they express specific 
characteristics that can be used as markers for identification of these phenotypes. M1 
macrophages upregulate nitric oxide (NO) production and pro-inflammatory cytokines 
such as IL-12 and TNF-alpha while M2 macrophages increase expression of Arginase 1 




Hydrogel Delivery System 
 Since the heart tissue is a highly vascularized environment, direct administration 
of a small protein such as IL-4 will be highly inefficient. Previous studies in our 
laboratory have shown promising use of a polyethylene glycol-Maleimide (PEG-MAD) 
based protease sensitive hydrogel to deliver therapeutics to infarct tissue in experimental 
MI models.[9] Since injectable hydrogel elicits no inflammatory response, it was used as a 
model for our PEG-MAL hydrogel. The PEG-MAL hydrogel is composed of a 4-arm 
PEG macromere end functionalized with maleimide groups that allow for 
functionalization with any cystine containing peptides and a cell adhesion molecule 
(RGC) (figure 1). The main component of this hydrogel is the protease sensitive peptide 
cross-linker (VPM). As the dominant M1 macrophage population in the post-MI heart 
upregulates proteases in the environment, hydrogel degrades over time thereby 
facilitating the sustained release of IL-4. 
 
 
Figure1. PEG-MAL Hydrogel Delivery Mechanism.[9] Proteases present in the 






 The regenerative properties resulting from the switch in the activation types of 
macrophages have been analyzed in several disease and regeneration models[10,11].  For 
instance, similar to the heart following MI, in skeletal muscle repair, initially, the injured 
muscle only recruited the pro-inflammatory phenotype; however a shift occurred in 
which the muscle later recruited anti-inflammatory activated macrophages.[12] This 
phenotypic switch stimulated myogenesis and fiber growth. Further, in a study induced 
peripheral nerve repair using M1 or M2 activated macrophages.[10]  
 Similarly, efforts to manipulate macrophages to bring about regenerative effects 
have been attempted on several different models. In a peripheral never regeneration 
model, when conduits containing IFN-y (to shift macrophages to M1 phenotype) or IL-4 
(to shift macrophages to M2 phenotype) was implanted in the nerve gap injury, it was 
demonstrated that IL-4 containing conduits greatly increased the proliferation of 
Schwann cells and axons through the conduits.[10] This strategy is very similar to the one 
we are implementing for cardiac repair following MI and further provides validation that 
it could be a viable strategy.  
 Further, in an MI model, phosphatidylerine (PS) presenting liposomes mimicing 
apoptotic cells were used [13] to switch pro-inflammatory macrophages to anti-
inflammatory macrophages. M2 activation has been observed with intravenous injections 
of phosphatidylerine (PS) – presenting liposomes that adhere to the macrophage and 
mimic a “death” signal. This signal recruits anti-inflammatory macrophages to the heart 
following a MI. PS-presenting liposomes affectively increased of the CD206 marker for 
M2, and decreased the M1 marker CD86. In addition, the M2 phenotype was expressed at 
least a day earlier than the time frame usually observed (day 4-7) following MI than 
compared to the control groups that received MI but not the PS-liposome treatment. 
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However, it is unknown whether the PS-presenting liposomes mimicking apoptotic cells 
could have adverse effects systemically. Our approach utilizes a hydrogel delivery system 
to directly target the activated macrophages in the heart.  
 One of the aspects of our study is to assess the paracrine effect of the activated 
macrophages, specifically stem cells. This is done by collecting the conditioned media 
from activated macrophages and analyzing and testing the effect of this media on other 
cell types of interest. Several studies in the literature illustrate similar concepts. In one 
study, neuron survival and neurite regeneration induced by myelin-activated 
macrophages were assessed. After four days, in vitro data showed the myelin-activated 
peritoneal macrophage conditioned media had about 56% survival of the neurons 
compared to the control of just macrophage condition media with 40% survival.[11] The 
mechanism for neural regeneration by this myelin-activated macrophage is unknown. It is 
possible that the myelin was ingested by the macrophages and are causing phenotypic 
changes, or changes in the secretome (proteins, microRNA etc) of these macrophages.  
 Our approach utilizes cytokine IL-4, a molecule traditionally known to bring 
about M2 phenotype. Several studies in literature have utilized various other approaches 
to activate macrophages towards M2 phenotype. In one study, co-culturing mesenchymal 
stem cells (MSC) with peripheral blood monocytes caused M2 phenotype in these 
monocytes, and this was attributed to the regenerative properties of MSCs. In vitro data 
showed an increase in the M2 marker CD206 and anti-inflammatory TH2-related 
cytokine IL-10[14]. However, the MSC co-cultured macrophages also retained high levels 
of inflammatory cytokines. This new macrophage subset now has both properties of the 
M1 and M2 phenotype and therefore it is unclear whether this approach is effective in 
reducing inflammation. Another study utilized SEW2871, a macrophage recruiting agent, 
in conjunction with platelet rich plasma (PRP) implanted in a hydrogel to analyze their 
effects on bone remodeling.[15]  
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 Currently, research with regard to macrophage activation utilizing hydrogels 
applied to the cardiac region is not prevalent. Our aim is to encapsulate IL-4, a known 
macrophage modulator, in a hydrogel and deliver it to the heart in order to shift the pro-
inflammatory phenotype to the anti-inflammatory phenotype in the heart earlier than the 
pre-determined time. We believe that this strategy could reduce the overwhelming pro-
inflammatory response and enhance anti-inflammatory macrophage response in the injury 





MATERIALS AND METHODS 
 Firstly, we aim to validate our treatments In vitro. Our goal is to determine if 
macrophages can be activated through IL-4 and IFNy plus LPS. Additionally, we want to 
characterize wound-healing properties that are associated with our treatment. Finally, we 
want to test our approach In vivo and assess the functionality. 
 
RAW Macrophage Modulation 
 RAW macrophages are a widely accepted cell line for In vitro experiments due to 
their long life span. In a 6-well tissue culture plate, about a million macrophages were 
plated in each well. Following adherence of the cells, media was changed to serum free 
media to quiecse the cells for 4 hours following which the cells were either treated with 
10ng/mL of IL-4 for M2 activation or 10ng/mL of IFN-y and 0.1ug/mL of LPS for M1 
activation while one treatment group just contained serum free media as untreated 
control. After 24 hours, the conditioned media (CM) from each well was collected to 
determine NO production via Greiss assay. The cells were extracted using Trizol reagent 
for RNA isolation and gene expression analysis conducted via qPCR. The characteristic 
markers of M1 and M2 phenotypes were analyzed in samples from all treatment groups 
and compared against the untreated control group. To determine the gene expression 
levels, qPCR was used with gene-specific primers. The M1 marker TNF-a and M2 
markers Arg 1 and Mrc1 as well as the house-keeping gene Hprt1 to normalize gene 
expression were analyzed. The ∆∆CT method was used to quantify fold changes in gene 
expression normalized to Hprt1 mouse house-keeping gene.  
 
Bone Marrow Macrophage Modulation 
 Bone marrow derived macrophages more accurately represent the internal 
environment due to the fact that they are a primary cell line. Therefore, our treatments 
were applied to these primary cells. Bone marrow was harvested in the femur and tibia of 
a rat. The cells were plated for seven days on a petri dish in 20% FBS RPMI media. The 
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cells were then allowed to adhere to a T-75 cell culture plate for a day. In a 6 well tissue 
culture plate, approximately 1 million cells/mL were treated with 10ng/mL of IL-4 (for 
M2 activation) or 1ng/mL of IFN-y and 0.1ug/mL of LPS (for M1 activation) in serum 
free media. After 24 and 48 hours, the conditioned media from each well was collected to 
determine NO production via Greiss assay and the cells were scraped in PBS to be used 
for an Arginase assay.  
 
Cardiac Progenitor Cell (CPC) Migration 
. Cardiac progenitor cells have been increasingly identified as a new therapy for 
cardiac repair post MI. Increased recruitment of CPCs can lead to an increased wound-
healing response. CPCs were fluorescently labeled with CMRA in serum free Ham’s 
media. Using a modified Boyden chamber assay in a 24-well plate, 100,000 CPCs in 
100uL were placed in the top chamber while 300uL of treated macrophage CM was 
placed in the bottom. The plate was incubated in 37 degrees Celsius overnight and read 
with a fluorescent plate reader.  
 
Quantification of Myocardial Fibrosis 
 After exposure to a MI, through occlusion to the coronary artery, evaluating the 
ratio of fibrotic to healthy heart tissue will assess the effects of our treatment In vivo. The 
animal was sacrificed and the heart was embedded in paraffin. Sections 7um thick were 
mounted onto slides. After submersion in Histoclear for 15 min, the section was 
rehydrated in a series of ethanol dilutions (100%,90%,70%) and placed in picoeirius red 








RAW Macrophage Modulation 
  In a RAW macrophage cell line, IL-4 treated cells exhibited a significant increase 
MRC-1 and Arg1 gene expression, which indicates activation towards an M2 functional 
phenotype, while IFNγ plus LPS treated cells show increased expression of TNF-a and 
high levels of NO, characteristics of M1 macrophages (n: 1-3, p <0.05) (figure 2). These 
results confirm the plasticity of macrophages and our ability to modulate their phenotype 
















Bone Marrow Macrophage Modulation 
 Macrophages treated for 48 hours with IFNy with LPS (M1) and IL-4 (M2) showed a 
significant increase in nitric oxide (figure 3) and Arginase 1 (figure 4) respectively, 
which coincides with the RAW macrophage data. However when macrophages are 





Figure 2. Characterization of macrophage activation markers. All gene 




conditioned media has high concentrations of nitric oxide. When macrophages are 
simultaneously treated with IFNy plus LPS and IL-4 for 48 hours, cells express high 
concentrations of Arginase 1. This suggests that once macrophages are polarized down an 
M1 lineage it is more difficult to shift the macrophages to an M2 phenotype. The 
simultaneous activation shows that it is more advantageous to have IL-4 present in the 
environment as soon as macrophages arrive to the injury site to achieve a greater 








Figure 3. Nitric oxide concentration from bone marrow macrophage 
conditioned media. All media was used after 48 hours exposure to treatment. 
(n=5, *p<.05, ***p<.0001). 
Figure 4. Arginase 1 concentration from bone marrow macrophage 
conditioned media. All media was used after 48 hours exposure to treatment. 




 The percentage of CPC migration increased 70% with IL-4 CM relative to the 
control. However we also wanted to assess the migratory capabilities of just the 
treatments alone in the media. This concluded little variation in percent migration due to 
the treatment alone, which confirms that the CPC migration from IL-4 CM is not just due 
to the IL-4 in the media, but due to the factors released by M2 macrophage subset. 
Therefore, the factors that the M2 macrophage subset secrete into the environment are 







Quantification of Myocardial Fibrosis 
 The quantitative data was not significant however, qualitative analysis potentially 
shows a decrease in fibrotic tissue (red) and increase in healthy tissue (yellow) from the 
MI heart to the IL-4 hydrogel treated MI heart 21 days after the MI occurred (figure 6). 
This suggests that the IL-4 hydrogel treatment could have long-term regenerative 
properties, which is beneficial for treating chronic MI. 
 
 
Figure 5. Percentage of CPC migration. All conditioned media was used from 48 hours of 
















Figure 6. Myocardial fibrosis day 21. All sections were captured under the same exposure 
time  





 In vitro data proved that when RAW and bone marrow derived macrophages are 
treated with either IFNY plus LPS or IL-4 macrophages will polarize towards an M1 or 
M2 subset respectively. We saw an increase in the expression of MRC-1 and Arg1 with 
the M2 polarized macrophages and an increase in TNF-a expression and NO production 
in M1 polarized macrophages. Additionally, we saw the effects of staggered versus 
simultaneous activation. Simultaneous activation is more beneficial for polarizing 
macrophages to the M2 phenotype. Once macrophages are polarized to the M1 
phenotype, they have less potential to polarize to the M2 phenotype. Therefore, it’s 
crucial that IL-4 is present in the environment once macrophages arrive to the injury site. 
In order to determine the wound healing effects of IL-4 treated macrophages in vitro, we 
aim to evaluate cardiac progenitor cell (CPC) recruitment due to the CPC’s effect on the 
viability of cardiac cells. Although the fibrosis staining of treated heart tissue was not 
significant, a gene and/or protein expression analysis could determine the healing 
potential of IL-4 treated macrophages post MI. If IL-4 posses healing potential in vitro, 
application of IL-4 after a myocardial infarction could increase the patient quality of life 
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